These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 17882256)

  • 21. Neuroprotection: extrapolating from neurologic diseases to the eye.
    Danesh-Meyer HV; Levin LA
    Am J Ophthalmol; 2009 Aug; 148(2):186-191.e2. PubMed ID: 19464671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On the hypes and falls in neuroprotection: targeting the NMDA receptor.
    Villmann C; Becker CM
    Neuroscientist; 2007 Dec; 13(6):594-615. PubMed ID: 17911221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [NMDA receptor antagonists: a new treatment for neuropathic pain].
    Pud D; Eisenberg E
    Harefuah; 1999 Apr; 136(7):564-7. PubMed ID: 15532603
    [No Abstract]   [Full Text] [Related]  

  • 24. Memantine: update on the current evidence.
    Möbius HJ
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S47-54. PubMed ID: 12973750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retinal ganglion cells, glaucoma and neuroprotection.
    Lipton SA
    Prog Brain Res; 2001; 131():712-8. PubMed ID: 11420983
    [No Abstract]   [Full Text] [Related]  

  • 26. Future of neuroprotective drugs in doubt.
    Birmingham K
    Nat Med; 2002 Jan; 8(1):5. PubMed ID: 11786882
    [No Abstract]   [Full Text] [Related]  

  • 27. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
    Parsons CG; Stöffler A; Danysz W
    Neuropharmacology; 2007 Nov; 53(6):699-723. PubMed ID: 17904591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotection by tosyl-polyamine derivatives through the inhibition of ionotropic glutamate receptors.
    Masuko T; Namiki R; Nemoto Y; Miyake M; Kizawa Y; Suzuki T; Kashiwagi K; Igarashi K; Kusama T
    J Pharmacol Exp Ther; 2009 Nov; 331(2):522-30. PubMed ID: 19644042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacotherapy for degenerative dementias].
    Maloteaux JM
    Bull Mem Acad R Med Belg; 2005; 160(1-2):109-17; discussion 118-22. PubMed ID: 16116815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease.
    Leaver KR; Allbutt HN; Creber NJ; Kassiou M; Henderson JM
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1388-94. PubMed ID: 18785982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
    Popovic N; Brundin P
    Int J Pharm; 2006 May; 314(2):120-6. PubMed ID: 16529886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel benzopolycyclic amines with NMDA receptor antagonist activity.
    Valverde E; Sureda FX; Vázquez S
    Bioorg Med Chem; 2014 May; 22(9):2678-83. PubMed ID: 24698811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An overview of the pathophysiology of neurodegenerative disorders.
    Willner C
    Altern Ther Health Med; 2004; 10(4):26-34; quiz 35, 96. PubMed ID: 15285272
    [No Abstract]   [Full Text] [Related]  

  • 35. NMDA receptor antagonists: tools in neuroscience with promise for treating CNS pathologies.
    Köhr G
    J Physiol; 2007 May; 581(Pt 1):1-2. PubMed ID: 17331982
    [No Abstract]   [Full Text] [Related]  

  • 36. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection.
    Stone TW; Forrest CM; Darlington LG
    FEBS J; 2012 Apr; 279(8):1386-97. PubMed ID: 22248239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
    Song MS; Rauw G; Baker GB; Kar S
    Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eliciting paresthesias for peripheral nerve block: a harmful clinical standard?
    Kiefer RT
    Anesth Analg; 2001 Mar; 92(3):795-6. PubMed ID: 11226122
    [No Abstract]   [Full Text] [Related]  

  • 39. [Antibodies, antihypertensive drugs, antioxidants. Can they prevent Alzheimer disease?].
    MMW Fortschr Med; 2003 Aug; 145(33-34):60. PubMed ID: 14526584
    [No Abstract]   [Full Text] [Related]  

  • 40. GMP prevents excitotoxicity mediated by NMDA receptor activation but not by reversal activity of glutamate transporters in rat hippocampal slices.
    Molz S; Tharine DC; Decker H; Tasca CI
    Brain Res; 2008 Sep; 1231():113-20. PubMed ID: 18655777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.